| (Values in U.S. Thousands) | Jul, 2021 | Apr, 2021 | Jan, 2021 | Jul, 2020 | Apr, 2020 |
| Sales | 3,382 | 5,667 | 2,647 | 1,861 | 2,215 |
| Sales Growth | -40.32% | +114.09% | +42.24% | -15.98% | +48.66% |
| Net Income | -7,670 | -2,969 | -1,867 | -1,726 | -1,176 |
| Net Income Growth | -158.34% | -59.03% | -8.17% | -46.77% | +27.18% |
Valeo Pharmainc (VPH.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its products include Benztropine, Synacthen, M-Eslon, and among others.
Fiscal Year End Date: 10/31